These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 28870460)

  • 1. Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria.
    Ertas R; Ozyurt K; Ozlu E; Ulas Y; Avci A; Atasoy M; Hawro T; Maurer M
    J Allergy Clin Immunol; 2017 Dec; 140(6):1749-1751. PubMed ID: 28870460
    [No Abstract]   [Full Text] [Related]  

  • 2. IgE and D-dimer baseline levels are higher in responders than nonresponders to omalizumab in chronic spontaneous urticaria.
    Cugno M; Genovese G; Ferrucci S; Casazza G; Asero R; Marzano AV
    Br J Dermatol; 2018 Sep; 179(3):776-777. PubMed ID: 29582427
    [No Abstract]   [Full Text] [Related]  

  • 3. Elevated IgE to tissue factor and thyroglobulin are abated by omalizumab in chronic spontaneous urticaria.
    Cugno M; Asero R; Ferrucci S; Lorini M; Carbonelli V; Tedeschi A; Marzano AV
    Allergy; 2018 Dec; 73(12):2408-2411. PubMed ID: 30076634
    [No Abstract]   [Full Text] [Related]  

  • 4. Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab.
    Weller K; Ohanyan T; Hawro T; Ellrich A; Sussman G; Koplowitz J; Gimenez-Arnau AM; Peveling-Oberhag A; Staubach P; Metz M; Maurer M
    Allergy; 2018 Dec; 73(12):2406-2408. PubMed ID: 30076605
    [No Abstract]   [Full Text] [Related]  

  • 5. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change.
    Ertas R; Ozyurt K; Atasoy M; Hawro T; Maurer M
    Allergy; 2018 Mar; 73(3):705-712. PubMed ID: 29083482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria.
    Gericke J; Metz M; Ohanyan T; Weller K; Altrichter S; Skov PS; Falkencrone S; Brand J; Kromminga A; Hawro T; Church MK; Maurer M
    J Allergy Clin Immunol; 2017 Mar; 139(3):1059-1061.e1. PubMed ID: 27838346
    [No Abstract]   [Full Text] [Related]  

  • 7. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients.
    Marzano AV; Genovese G; Casazza G; Fierro MT; Dapavo P; Crimi N; Ferrucci S; Pepe P; Liberati S; Pigatto PD; Offidani A; Martina E; Girolomoni G; Rovaris M; Foti C; Stingeni L; Cristaudo A; Canonica GW; Nettis E; Asero R
    J Eur Acad Dermatol Venereol; 2019 May; 33(5):918-924. PubMed ID: 30451325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria.
    Straesser MD; Oliver E; Palacios T; Kyin T; Patrie J; Borish L; Saini SS; Lawrence MG
    J Allergy Clin Immunol Pract; 2018; 6(4):1386-1388.e1. PubMed ID: 29175369
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment with omalizumab or cyclosporine for resistant chronic spontaneous urticaria.
    Koski R; Kennedy KK
    Ann Allergy Asthma Immunol; 2017 Nov; 119(5):397-401. PubMed ID: 29150066
    [No Abstract]   [Full Text] [Related]  

  • 10. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
    Metz M; Ohanyan T; Church MK; Maurer M
    J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial D-dimer plasma levels in a patient with chronic spontaneous urticaria developing resistance to omalizumab.
    Asero R
    Clin Exp Dermatol; 2017 Aug; 42(6):667-669. PubMed ID: 28691309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab in chronic spontaneous and inducible urticaria: a 9 year retrospective study in Portugal.
    Marcelino J; Costa AC; Mendes A; Alonso E; Cabral Duarte F; Pedro E; Pereira-Barbosa M
    Eur Ann Allergy Clin Immunol; 2018 Jul; 50(4):169-176. PubMed ID: 29479938
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
    Maurer M; Altrichter S; Bieber T; Biedermann T; Bräutigam M; Seyfried S; Brehler R; Grabbe J; Hunzelmann N; Jakob T; Jung A; Kleine-Tebbe J; Mempel M; Meurer M; Reich K; Ruëff F; Schäkel K; Sengupta K; Sieder C; Simon JC; Wedi B; Zuberbier T; Mahler V; Staubach P
    J Allergy Clin Immunol; 2011 Jul; 128(1):202-209.e5. PubMed ID: 21636116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basophil FcɛRI expression is linked to time to omalizumab response in chronic spontaneous urticaria.
    Deza G; Bertolín-Colilla M; Sánchez S; Soto D; Pujol RM; Gimeno R; Giménez-Arnau AM
    J Allergy Clin Immunol; 2018 Jun; 141(6):2313-2316.e1. PubMed ID: 29518420
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria.
    Saini SS; Omachi TA; Trzaskoma B; Hulter HN; Rosén K; Sterba PM; Courneya JP; Lackey A; Chen H
    J Invest Dermatol; 2017 Apr; 137(4):958-961. PubMed ID: 27939380
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of omalizumab in the treatment of chronic urticaria.
    Cordeiro Moreira AS; Rosmaninho Lopes de Soares E Silva MI; Pereira Guilherme MA; da Silva Ferreira JA; Fonseca Moreira da Silva JP
    Eur Ann Allergy Clin Immunol; 2016 Nov; 48(6):242-246. PubMed ID: 27852430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Omalizumab in Patients with Chronic Spontaneous Urticaria and Its Association with Serum IgE Levels and Eosinophil Count.
    Tamer F; Gulru Erdogan F; Dincer Rota D; Yildirim D; Akpinar Kara Y
    Acta Dermatovenerol Croat; 2019 Jun; 27(2):101-106. PubMed ID: 31351504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
    Ghazanfar MN; Holm JG; Thomsen SF
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omalizumab also successful in chronic urticaria.
    Spector SL; Tan RA
    J Allergy Clin Immunol; 2008 Mar; 121(3):784; author reply 784-5. PubMed ID: 18328900
    [No Abstract]   [Full Text] [Related]  

  • 20. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.
    Kaplan AP; Giménez-Arnau AM; Saini SS
    Allergy; 2017 Apr; 72(4):519-533. PubMed ID: 27861988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.